|
Drug Repositioning Strategies: Innovative strategies to boost pipeline productivity
CHAPTER 1: INTRODUCTION
- Summary
- Introduction
- Why reposition?
- The aims of repositioning
- What has made repositioning
possible?
- Structure of the report
CHAPTER 2: REPOSITIONING
FAILED COMPOUNDS
- Summary
- Introduction
- Technology platforms for
indications discovery
- Gene Logic
- Sosei
- Melior Discovery and
Melior Pharmaceuticals
- KineMed
- BrainCells Inc and Dynogen
- Repositioning – the Synosis
business model
- Pharmacogenomics
- Conclusions
CHAPTER 3: REPOSITIONING
MARKETED COMPOUNDS
- Summary
- Introduction
- Repositioning strategies
- Indications discovery with
new technologies
- Bionaut Pharmaceuticals
- DanioLabs and VASTox
- Applying a therapeutic
focus
- Mining databases for new
indications
- Drug combinations
- Repositioning in the public
sector
- Screening technologies
- Molecular libraries
- Repositioning based on
advancing knowledge of disease
- Conclusions
CHAPTER 4: DRUG REPOSITIONING
THROUGH REFORMULATION
- Summary
- Introduction
- Controlled delivery and
chronotherapeutics
- Non-invasive delivery routes
- Inhaled delivery
- Intranasal delivery
- Transdermal delivery
- Pro-drugs
- Targeted delivery
- nab TM technology
- Dendrimers
- BioSiliconTM
- Conclusions
CHAPTER 5: INTELLECTUAL
PROPERTY AND REGULATORY ISSUES
- Summary
- Introduction
- Patent issues
- Regulatory considerations
- Filing routes
- Other issues
- Non-patent market exclusivity
- The non-approval route
- Pharmacogenomics
- Conclusions
CHAPTER 6: CHALLENGES OF DRUG
REPOSITIONING
- Summary
- Introduction
- Challenges and obstacles to
successful drug repositioning
- Proof of concept clinical
trials
- New drug targets with
novel mechanisms of action
- Safety remains a key issue
for early stage stalled drugs
- Data and IP issues
- Development of combination
products
- Indications discovery as
part of a long-term lifecycle management
program
- Reformulation
CHAPTER 7: TRENDS AND
OPPORTUNITIES
- Summary
- Introduction
- The future for repositioning
- Business models and the
future
- Repositioning marketed
drugs
- Market size estimates
- Impact of repositioning on
R&D
- Future financial rewards
of repositioning marketed drugs
- Market potential of
reformulated drugs
- Conclusions
- Bibliography
|
